Azenta

Personalized Medicine And Automation Will Drive Future Market Expansion

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

28 May 25

AnalystConsensusTarget's Fair Value

US$33.00

6.2% undervalued

04 Sep

US$30.97

-29.8%

3.9%

-29.8%

3.9%

You can edit this narrative until May 28 8:09 PM. Then, changes will post as Updates.

Author's Valuation

US$336.2% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

US$33

6.2% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

1.03%

Life Sciences revenue growth rate

0.31%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.33%

Calculation

US$34.48m

Earnings '28

54.25x

PE Ratio '28

US$1.87b

Market Cap '28

US$1.87b

Market Cap '28

46.62m

No. shares '28

US$40.13

Share Price '28

US$40.13 Share Price '28

Discounted to 2025 @ 7.21% p.a.

US$32.56

Fair Value '25